LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

Search

TG Therapeutics Inc

Chiusa

SettoreSettore sanitario

30.74 -0.52

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

30.66

Massimo

30.88

Metriche Chiave

By Trading Economics

Entrata

363M

391M

Vendite

21M

162M

P/E

Media del settore

11.235

78.892

Margine di Profitto

241.727

Dipendenti

374

EBITDA

-4.9M

33M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+39.75% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-405M

4.9B

Apertura precedente

31.26

Chiusura precedente

30.74

Notizie sul Sentiment di mercato

By Acuity

50%

50%

157 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

TG Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

24 dic 2025, 21:41 UTC

Acquisizioni, Fusioni, Takeovers

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

26 dic 2025, 20:22 UTC

Discorsi di Mercato

Oil Loses Ground On Russia-Ukraine Peace Efforts -- Market Talk

26 dic 2025, 20:13 UTC

Discorsi di Mercato

U.S. Natural Gas Gains on Colder Weather Outlook -- Market Talk

26 dic 2025, 19:24 UTC

Acquisizioni, Fusioni, Takeovers

Nvidia's Groq Deal Is an Instagram Moment -- With 1 Big Risk -- Barrons.com

26 dic 2025, 17:45 UTC

Discorsi di Mercato

U.S. Diesel Down on Lower Crude Prices, Freight-Sector Lull -- Market Talk

26 dic 2025, 15:52 UTC

Discorsi di Mercato

Oil Futures Turn Lower After Steady Start -- Market Talk

26 dic 2025, 14:58 UTC

Discorsi di Mercato

Silver, Gold Reach New Highs Amid Geopolitical Tension -- Market Talk

26 dic 2025, 14:41 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Look to End Week Higher -- Market Talk

26 dic 2025, 14:28 UTC

Discorsi di Mercato

Dollar Indexes Flat as Yen Rally Wanes -- Market Talk

26 dic 2025, 13:47 UTC

Discorsi di Mercato

Oil Futures Steady in Thin Holiday Trade -- Market Talk

26 dic 2025, 07:22 UTC

Discorsi di Mercato

Comex Gold Futures' Strong Bullish Momentum in Play, Chart Shows -- Market Talk

26 dic 2025, 05:03 UTC

Discorsi di Mercato

Malaysian Ringgit Likely to Face Pressure From Dollar Strength in 1Q -- Market Talk

26 dic 2025, 03:38 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

26 dic 2025, 03:38 UTC

Discorsi di Mercato

Korean Won Strengthens, Supported by Verbal Interventions -- Market Talk

26 dic 2025, 02:44 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

26 dic 2025, 02:44 UTC

Discorsi di Mercato

Singapore Dollar Weakens Slightly on Likely Position Adjustments -- Market Talk

26 dic 2025, 01:39 UTC

Discorsi di Mercato

China's Central Bank Signals Possibility of Easing Policy in Coming Months -- Market Talk

26 dic 2025, 01:14 UTC

Discorsi di Mercato

Oil Edges Higher Amid Geopolitical Tensions -- Market Talk

26 dic 2025, 00:34 UTC

Discorsi di Mercato

Yen Mostly Weakens Amid Risk-on Sentiment -- Market Talk

26 dic 2025, 00:15 UTC

Discorsi di Mercato

Nikkei Gains 0.6%, Led by Tech, Videogame Stocks -- Market Talk

25 dic 2025, 23:42 UTC

Discorsi di Mercato

Nikkei May Trade in Range; Yen in Focus -- Market Talk

25 dic 2025, 23:40 UTC

Discorsi di Mercato

Gold Edges Higher Amid Geopolitical Risks -- Market Talk

25 dic 2025, 00:20 UTC

Acquisizioni, Fusioni, Takeovers

Nike Climb Boosts Dow, S&P 500 -- 2nd Update

24 dic 2025, 22:22 UTC

Acquisizioni, Fusioni, Takeovers

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

24 dic 2025, 21:26 UTC

Acquisizioni, Fusioni, Takeovers

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

24 dic 2025, 19:35 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

24 dic 2025, 19:35 UTC

Discorsi di Mercato

Treasury Yields Decline Ahead of Christmas -- Market Talk

24 dic 2025, 19:09 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Global Equities Roundup: Market Talk

24 dic 2025, 19:09 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

ServiceNow's Armis Acquisition Shouldn't Fuel Fears That Seat-Based Model Threatened -- Market Talk

24 dic 2025, 19:06 UTC

Discorsi di Mercato

Oil Futures Little Changed in Light Pre-Holiday Trade -- Market Talk

Confronto tra pari

Modifica del prezzo

TG Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

39.75% in crescita

Previsioni per 12 mesi

Media 43 USD  39.75%

Alto 60 USD

Basso 13 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per TG Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

4 ratings

3

Acquista

0

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

N/A / 34.86Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

157 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
help-icon Live chat